MeiraGTx Holdings plc (MGTX)

NASDAQ • Healthcare

$9.21

-$0.55 (-5.7%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$9.7

Previous Close$9.21

Day Range$9.08 - $9.72

Avg. Volume (3M)906K

Market Cap$884.5M

P/E Ratio12.1

52 Week Range

$6.62$15.35

Next EarningsIn 18 daysNov 12, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$321.4M100%

Gross Profitminus cost of goods$314.2M98%

Operating Incomeminus R&D and overhead$244.4M76%

Net Incomeminus taxes and the rest$160.7M50%

In plain terms: out of every $100 in revenue, MeiraGTx Holdings plc keeps $50 as net profit.

Fundamentals & Financials

Revenue (TTM)

$397.5M

Net Income (TTM)

$78.9M

EPS (TTM)

$0.76

ROA (TTM)

19.92%

Current Ratio

3.76

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+7.7%Q3 2025-$0.48

-24.0%Q4 2025-$0.62

+131.7%Q1 2026$0.19

-32.6%Q2 2026-$0.57

+473.1%Q3 2026$1.71

Nov 12

in 18 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +473.1%

Revenue for MeiraGTx Holdings plc moved higher year over year in the second fiscal quarter of 2026, reported August 13, 2026, as the company continued advancing its genetic medicine programs across inherited retinal disease, xerostomia, and neurologic disorders. Operating cash flow was negative at roughly $38.5 million, reflecting the cash demands of running clinical-stage development alongside its platform work. For the next period, consensus calls for EPS of -$0.46 on revenue of $7.0 million.

Next report — what to expect

MeiraGTx Holdings plc (MGTX) reports on November 12, 2026. Wall Street is looking for EPS of -$0.46 on revenue of $7.0 million. For trailing context, revenue rose +8608.6% year over year last quarter. MGTX has beaten EPS in 3 of its 8 most recent quarters.

View full earnings history

About MeiraGTx Holdings plc

MeiraGTx Holdings plc is a NASDAQ-listed biotechnology company developing genetic medicines for inherited retinal disease, xerostomia, and neurologic disorders. In FY2025, it generated $81.4 million in revenue. Founded in 2015, MeiraGTx operates from New York City and has built its business around a pipeline of clinical-stage programs and platform technology.

Name

MeiraGTx Holdings plc

CEO

Alexandria Forbes

Website

www.meiragtx.com

Industry

Healthcare

Year Founded

2015

Employees

393

Today's Snapshot

AI-generated

MGTX closed 5.7% lower at 9.21, in line with a weaker sector.

Trading Volume

Below 10d avg (744.8K)

589.6K

vs S&P 500 Today

Strong Underperformance

-5.21%

Updated: October 23, 2026 at 20:11 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

MGTX is exhibiting a bearish technical profile as the stock trades near $9.21, with trend strength tilted to the downside and clear distribution. ADX around 36 indicates a strong directional move while price sits below its short- and long-term moving averages, reinforcing the downtrend. Momentum measures are negative—RSI in the low 30s and a deeply negative CCI—while MACD is below zero, suggesting limited buying conviction. Volatility is notable given an ATR near $0.57 (about 6%), and OBV points to net selling; the classic pivot sits above the market. Technical takeaway: Strong Sell — downtrend and distribution dominate.

All signals

EMA (5 indicators)$9.81 - $11.41
Sell
RSI (14)32.19
Neutral
Stochastic %K (14, 3, 3)23.66
Neutral
MACD Level (12, 26)-0.72
Neutral

Peers & Related Assets

KRYSKrystal Biotech, Inc.

$311.5-2.7%

NTLAIntellia Therapeutics, Inc.

$11.21+0.5%

SANASana Biotechnology, Inc.

$2.33-1.7%

FDMT4D Molecular Therapeutics, Inc.

$10.8-8.9%

RGNXREGENXBIO Inc.

$6.68-6.8%

QUREuniQure N.V.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.